BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Both have attracted considerable attention from Wall Street recently.
Overview
BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) burst onto the scene during the pandemic. Both developed and marketed some of the most successful mRNA-based coronavirus vaccines and were handsomely rewarded for it. However, their financial results have worsened as the pandemic has waned, and they have lagged broader equities over the past five years. Now for the good news: BioNTech and Moderna may have bright futures as they advance their vaccine candidates. But which one will deliver stronger returns?
Image source: Getty Images.
BioNTech boasts a deep pipeline of candidates. One of the most promising products it is working on is called pumitamig. The biotech is developing it in collaboration with Bristol Myers Squibb (NYSE: BMY). What's so special about pumitamig? It is one of those newer cancer drugs dubbed potential "Keytruda Killers," or medicines that could challenge Merck's (NYSE: MRK) Keytruda, the world's best-selling cancer drug. BioNTech is testing pumitamig across several potential indications, including lung cancer, the leading cause of cancer death. We should see more clinical trial data from pumitamig within the next 18 months. Positive results could send BioNTech's shares soaring.
Details
Source
Originally published at www.fool.com.
Related Articles
- Oura files for IPO amid Americans’ obsession with tracking their sleep, steps and heart rates
- Intapp Chief Product Officer Thad Jampol Sells 25,000 Shares
- Tim Cook Grew Apple From a $350 Billion Company Into a Multi-Trillion-Dollar Giant Over Nearly 15 Years as CEO. Can John Ternus' Product-First Approach Extend That Compounding?